Regenxbio Inc (RGNX) — Titan Protect Analysis

RGNX

Regenxbio Inc

Healthcare · ·

$6.08

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$340M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.61

Based on estimated future earnings — lower means cheaper

Rev Growth

-92.8%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-196.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$19.00

+213% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 11 analysts covering this stock

About Regenxbio Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment

https://www.regenxbio.com

Country: United States Employees: 371 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.015

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0101

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.485

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-31.3%

Historical annualised return based on price data

Max Drawdown

-64.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.12

Moves slightly more than the broader market

52W High

$16.19

62% below the year high

52W Low

$5.46

11% above the year low

Avg Volume

1,200,241

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.60

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1,178.24

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-196.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,304.0%

Profit from core operations before interest and tax

Free Cash Flow

$-138,978,624

Negative — the business is spending more than it generates

Revenue (TTM)

$88M

Total revenue over the last 12 months

Net Income

$-290,012,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$50.00

Target Median

$19.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go